TSHA Taysha Gene Therapies Inc
1,592
$2.53
$0.15
(6.30%)
| Watchers | 1,592 |
| 52-Wk Low | $0.50 |
| 52-Wk High | $3.89 |
| Market Cap | $445.1M |
| Volume | 1.23M |
| 52-Wk High | $3.89 |
| 52-Wk Low | $0.50 |
Evaluating Taysha Gene Therapies: Insights From 7 Financial AnalystsBenzinga • about 1 month ago
Latest Ratings for TSHA
DateFirmActionFromTo Mar 2022BairdInitiates Coverage OnOutperform Mar 2022Wells FargoInitiates Coverage OnOverweight Dec 2021GuggenheimInitiates Coverage OnBuy
View...
Share to Feed
DALLAS, April 05, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for...
Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Get Free Report) gapped down before the market opened on Wednesday . The stock had previously closed at $2.71, but opened at $2.65. Taysha Gene Therapies...
Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA Get Free Report) have been assigned an average rating of Buy from the seven analysts that are covering the stock, Marketbeat...
Truist Financial analyst Joon Lee maintained a Buy rating on Taysha Gene Therapies (TSHA Research Report) today. The company's shares closed yest...
Taysha Gene Therapies (NASDAQ:TSHA Get Free Report)s stock had its buy rating reiterated by research analysts at Canaccord Genuity Group in a report issued on Thursday...
Taysha Gene Therapies (NASDAQ:TSHA Free Report) had its price target hoisted by Chardan Capital from $5.00 to $7.00 in a report issued on Thursday, Benzinga reports. They currently have a buy...
Gagnants
Le titre Etao International Co (NASDAQ:ETAO) a augment mardi de 361,39% 0,66 dollars lors de la session after-market.
L'action Taysha Gene Therapies (NASDAQ:TSHA) a mont de 25,77% 2,83...
Taysha Gene Therapies shares are climbing after the company reported its fiscal year 2023 results after the bell Tuesday. The company reported fiscal year 2023 losses of 96 cents per share, compared...
Figure 1
REVEAL Phase 1/2 Adolescent and Adult Trial Data from Cohort One
Data from first adult patient in REVEAL Phase 1/2 trial showed TSHA-102 (low dose, 5.7x1014 total vg) was...